inPractice® - Genotype 3 Patients

Management of Hepatitis C Infection

Authors: Jordan J. Feld, MD, MPH; Hemant Shah, MD, MScCH HPTE (More Info)
Editor In Chief: Stefan Zeuzem, MD
Last Reviewed: 1/9/21 (What's New)

Summary

AASLD/IDSA (Management Guidelines)^{[AASLD-IDSA HCV]} guidelines recommend glecaprevir/pibrentasvir and sofosbuvir/velpatasvir as preferred options for genotype 3 HCV–infected treatment-naive patients
EASL guidelines recommend DAA-based regimens for patients with genotype 3 HCV infection (Management Guidelines)^{[EASL HCV]}

Action required

Login now to access all of your entitled content
or
View additional options to gain access to this content

Keywords: Hepatitis C-Treatment